Butyrate decreases proinflammatory cytokine expression via inhibition of NF-κB activation and IκBα degradation, thereby reducing ECM degradation and intestinal barrier disruption in IBD [206]. This evidence concerns the gene NFKB1 and inflammatory bowel disease.